Prepare Yourself for Liftoff: Geron Corp. (GERN)

With 8.43 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.45 shares. The 52-week range on GERN shows that it touched its highest point at $3.73 and its lowest point at $1.68 during that stretch. It currently has a 1-year price target of $4.83. Beta for the stock currently stands at 0.56.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GERN was up-trending over the past week, with a rise of 15.30%, but this was up by 1.44% over a month. Three-month performance surged to 14.05% while six-month performance fell -29.90%. A look at the trailing 12-month EPS for GERN yields -0.34 with Next year EPS estimates of -0.36. For the next quarter, that number is -0.10. This implies an EPS growth rate of 7.21% for this year and -3.88% for next year. EPS is expected to grow by 5.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -16.28%.

Float and Shares Shorts:

At present, 543.06 million GERN shares are outstanding with a float of 451.67 million shares on hand for trading. On Jan 31, 2024, short shares totaled 40.69 million, which was 7.49% higher than short shares on Dec 29, 2023. In addition to Dr. John A. Scarlett M.D. as the firm’s Chairman of the Board, President & CEO, Dr. Andrew J. Grethlein serves as its Executive VP & COO.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GERN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With GERN analysts setting a high price target of $6.00 and a low target of $4.00, the average target price over the next 12 months is $4.83. Based on these targets, GERN could surge 184.36% to reach the target high and rise by 89.57% to reach the target low. Reaching the average price target will result in a growth of 128.91% from current levels.

Summary of Insider Activity:

Insiders traded GERN stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 11 while that of sell transactions has risen to 2 over the past year. The total number of shares bought during that period was 116,021 while 70,000 shares were sold.